Sign In
Buy ABMD
$381.02
+0 (+0%)
At Close: Mar 20, 2023
Abiomed (ABMD) Earnings Expected to Grow: Should You Buy?
02:01pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Abiomed (ABMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molina Healthcare (MOH) to Post Q3 Earnings: What to Expect
05:32pm, Monday, 24'th Oct 2022 Zacks Investment Research
Molina Healthcare's (MOH) Q3 results are expected to reflect better premiums and membership growth in its Medicaid and Medicare businesses, partly offset by steep general and administrative costs.
Abiomed's (ABMD) Latest Impella Offering Approved by the FDA
04:36pm, Friday, 21'st Oct 2022 Zacks Investment Research
Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.
Abiomed's (ABMD) Latest Impella Offering Approved by the FDA
02:18pm, Friday, 21'st Oct 2022
Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.
Why Abiomed (ABMD) Could Beat Earnings Estimates Again
04:10pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Abiomed (ABMD) Could Beat Earnings Estimates Again
01:33pm, Thursday, 20'th Oct 2022
Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
02:05pm, Thursday, 13'th Oct 2022 Benzinga
Upgrades
TD Securities upgraded the previous rating for BCE Inc (NYSE:BCE) from Hold to Buy. In the second quarter, BCE showed an EPS of $0.68, compared to $0.68 from the year-ago quarter. The current
AngioDynamics (ANGO) Q1 Earnings, Revenues Lag Estimates
03:19pm, Monday, 10'th Oct 2022 Zacks Investment Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2023.
Abiomed (ABMD) is an Incredible Growth Stock: 3 Reasons Why
02:18pm, Friday, 07'th Oct 2022
Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.
Abiomed: Correction Offers Good Buying Opportunity
01:27pm, Wednesday, 28'th Sep 2022
Abiomed's Impella range of micro heart pumps enjoy rising demand in the marketplace. The company's OXY-1 System cardiopulmonary support device has strong growth prospect.
Abiomed (ABMD) Posts Impellas Positive Study Results in Japan
09:47am, Wednesday, 21'st Sep 2022
Abiomed's (ABMD) latest multi-center, multi-society study of Impella-supported patients is expected to significantly improve patient outcomes.
Abiomed's (ABMD) Impella-Related Research Gets FDA Clearance
12:47pm, Monday, 19'th Sep 2022
Abiomed's (ABMD) latest regulatory clearances for clinical research of Impella heart pumps in AMI cardiogenic shock patients are expected to significantly improve patient outcomes.
3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio
09:47am, Friday, 02'nd Sep 2022
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Abiomed's (ABMD) Impella Favored by Latest Study Result
02:18pm, Wednesday, 17'th Aug 2022
Abiomed's (ABMD) Impella-supported high-risk PCI leads to significant improvements in cardiovascular patient outcomes, per latest study.
Why Shares of Abiomed Rose 18.4% in July
03:21pm, Monday, 08'th Aug 2022
The company's stock rose steadily throughout the month.
